This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: The Innovative Contributions of Andrew Kiely
Introduction
Andrew Kiely is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds aimed at treating infections. His work exemplifies the intersection of science and innovation, showcasing the potential of research to improve health outcomes.
Latest Patents
Andrew Kiely holds a patent for "Fused heterocycles as inhibitors of glutamate racemase (MURI)." This invention relates to novel compounds represented by formulas (I) or (II), along with their pharmaceutical compositions and methods of use. These compounds are designed to provide treatment or prophylaxis against infections, highlighting their therapeutic potential.
Career Highlights
Kiely is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca allows him to contribute to cutting-edge research and development in the pharmaceutical industry. His expertise and innovative mindset have positioned him as a valuable asset within the company.
Collaborations
Andrew Kiely has collaborated with notable colleagues, including Marshall Morningstar and Gregory Steven Basarab. These partnerships reflect the collaborative nature of scientific research, where diverse expertise can lead to groundbreaking discoveries.
Conclusion
In summary, Andrew Kiely is an accomplished inventor whose work in pharmaceutical innovation is making a significant impact. His patent for novel compounds demonstrates his commitment to advancing medical science and improving patient care.